Key Points
- To evaluate the cognitive-enhancing capabilities of the angiotensin II receptor antagonist DuP 753 in a mouse habituation model under baseline conditions and following scopolamine-induced impairment.
- Tested mice across repeated daily sessions using a two-compartment light-dark habituation paradigm.
- Administered oral DuP 753 (10.0 ng kg⁻¹ p.o.) alone or alongside intraperitoneal scopolamine (0.25 mg kg⁻¹ i.p.) to measure behavioral and exploratory parameters.
- DuP 753 (10.0 ng kg⁻¹ p.o.) enhanced baseline cognitive performance, decreasing latency to move from light to dark while increasing rearings, line crossings, and dark compartment dwell time.
- DuP 753 reversed cognitive deficits triggered by scopolamine (0.25 mg kg⁻¹ i.p.).
Structured PICO
PPopulationMice in a habituation paradigm
IInterventionDuP 753 (angiotensin II receptor antagonist) 10.0 ng kg-1 p.o.
OOutcomeCognitive performance (latency to move from the light to the dark compartment, rears, line crossings, and percentage of time spent in the dark compartment)surrogate
DuP 753, an angiotensin II receptor antagonist, demonstrates potential cognitive-enhancing effects in a mouse model, suggesting a role for angiotensin II in modulating mental function.